What is the BOND-003 study?

The BOND-003 study evaluates cretostimogene for high-risk BCG-unresponsive non-muscle invasive bladder cancer.

When will CG Oncology present at AUA?

CG Oncology will present at the AUA Annual Meeting from April 26-29, 2025.

What is the significance of the late breaker designation?

The late breaker designation highlights the study's potential to change urology practices.

Where is the AUA Annual Meeting held?

The AUA Annual Meeting will take place in Las Vegas, Nevada.

BOND-003 Study Selected as Late Breaker at AUA

[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_fullwidth_code _builder_version=”4.27.4″ _module_preset=”default” custom_css_free_form=”.breadcrumbs {|| position: fixed;|| left: 0;|| right: 0;|| z-index: 1000;|| display: flex;|| justify-content: center;|| padding: 0 24px;||}||||.breadcrumbs .breadcrumbContainer {|| width: 100%;|| max-width: 1110px;|| margin: 0 auto; || position: relative;||}||||.container {|| width:100% !important;|| padding-top:80px !important||}||.breadcrumbs::after {|| content: %22%22;|| height: 100%;|| width: 135px;|| background: linear-gradient(to left, rgba(255, 255, 255, 1), rgba(255, 255, 255, 0));|| position: absolute;|| right: 0;|| top: 0;||}||||@media (min-width: 1200px) {|| .breadcrumbs .breadcrumbContainer {|| max-width: 1110px;|| }||}||||@media (max-width: 1199px) and (min-width: 992px) {|| .breadcrumbs .breadcrumbContainer {|| max-width: 960px;|| }||}||||@media (max-width: 991px) and (min-width: 768px) {|| .breadcrumbs .breadcrumbContainer{|| max-width: 720px;|| }||}||||@media (max-width: 767px) and (min-width: 576px) {|| .breadcrumbs .breadcrumbContainer {|| max-width: 540px;|| }||}||||@media (max-width: 575px) {|| .breadcrumbs .breadcrumbContainer {|| max-width: 100%;|| }||}” global_colors_info=”{}”] Home CG Oncology to Participate… [/et_pb_fullwidth_code][/et_pb_section][et_pb_section fb_built=”1″ module_id=”pressReleasesWrapper” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||||false|false” custom_padding=”6px||||false|false” collapsed=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”15px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”PRESS RELEASE” module_class=”press-inner-title” _builder_version=”4.27.4″ _module_preset=”default” title_font=”Montserrat|700|||||||” title_text_align=”left” title_text_color=”#2b7de1″ width_tablet=”” width_phone=”276px” width_last_edited=”on|phone” height_tablet=”” height_phone=”34px” height_last_edited=”on|phone” custom_margin=”||||false|false” custom_margin_tablet=”||||false|false” custom_margin_phone=”||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||||false|false” global_colors_info=”{}”][/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”Montserrat|700|||||||” text_text_color=”#002169″ text_font_size=”24px” text_line_height=”1.3em” width=”1010px” width_tablet=”1010px” width_phone=”328px” width_last_edited=”on|phone” height=”93px” height_tablet=”93px” height_phone=”317px” height_last_edited=”on|phone” custom_margin_tablet=”” custom_margin_phone=”||||false|false” custom_margin_last_edited=”on|phone” text_line_height_tablet=”1.3em” text_line_height_phone=”1.3em” text_line_height_last_edited=”on|phone” global_colors_info=”{}”]

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”-50px||||false|false” custom_margin_tablet=”-50px||||false|false” custom_margin_phone=”-50px||||false|false” custom_margin_last_edited=”on|desktop” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.27.4″ _module_preset=”default” width_tablet=”” width_phone=”326px” width_last_edited=”on|phone” height_tablet=”” height_phone=”157px” height_last_edited=”on|phone” custom_margin_tablet=”” custom_margin_phone=”-90px||||false|false” custom_margin_last_edited=”on|phone” global_colors_info=”{}”]

💻 DESKTOP AUDIO PLAYER =============================== –>

📱 MOBILE AUDIO PLAYER =============================== –>

[/et_pb_code][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”-30px||||false|false” custom_margin_tablet=”-30px||||false|false” custom_margin_phone=”-30px||||false|false” custom_margin_last_edited=”on|desktop” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text content_tablet=”

– Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing,Paradigm-shifting Clinical Trials in Urology

– Additional updates from across CG Oncology’s clinical trial program, including translational data, planned

IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part of American Urological Association (AUA)’s Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s). Designed to showcase the exceptional, groundbreaking studies that are expected to change the day-to-day practice of urology, P2s are reserved for the most impactful studies and will be presented on the Plenary stage. Additionally, CG Oncology will present updates to ongoing clinical trials evaluating cretostimogene across the non-muscle invasive bladder cancer (NMIBC) treatment landscape which are expected to influence urology practice, as well as one interactive poster on translational data. The AUA Annual Meeting, scheduled from April 26-29, 2025, in Las Vegas, Nevada, is the largest gathering of urologists in the world, where leaders in the field share groundbreaking research, new guidelines and the latest advances in urologic medicine.

CG Oncology will have a series of key presentations and updates on cretostimogene grenadenorepvec including:

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ Session : Saturday Morning Plenary Session Presenter : Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona Presentation Date & Time: Saturday, April 26, 2025, 10:40 AM to 10:50 AM PT Location: Venetian Ballroom, The Venetian Convention & Expo Center

IP02-28: Translational Correlates using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Updated Analysis from the BOND-003 and CORE-001 Trials Session: IP02- Bladder Cancer- Non-Invasive I Presenter: Colin P. N. Dinney, MD; Professor and Chairman of the Department of Urology at The University of Texas M D Anderson Cancer Center Presentation Date & Time: Saturday, April 26, 2025, 7:00 AM to 9:00 AM PT Location: Marco Polo 701, The Venetian Convention & Expo Center

Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Session : Clinical Trials in Progress- Bladder Cancer Presenter : Trinity J. Bivalacqua, MD, PhD Professor of Urology and Oncology at the University of Pennsylvania Presentation Date & Time: Monday, April 28, 2025, 9:56 AM to 10:04 AM PT Location: Learning Lab, The Venetian Convention & Expo Center

Trial in Progress: BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Session: Clinical Trials in Progress- Bladder Cancer Presenter : Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona Presentation Date & Time : Monday, April 28, 2025, 9:40 AM to 9:48 AM PT Location : Learning Lab, The Venetian Convention & Expo Center

Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer Session: Clinical Trials in Progress- Bladder Cancer Presenter : Max Kates, MD, Associate Professor of Urology and Oncology and Director of the Bladder Cancer Program in the Brady Urological Institute at Johns Hopkins Presentation Date & Time : Monday, April 28, 2025, 10:28 AM to 10:36 AM PT Location : Learning Lab, The Venetian Convention & Expo Center Individuals can access the webcast via the link on the company’s Investor Relations website, https://ir.cgoncology.com . An archive will be available following the completion of the call.” content_phone=”

– Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology

– Additional updates from across CG Oncology’s clinical trial program, including translational data, planned

IRVINE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced BOND-003 study of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer has been selected as a late breaker as part of American Urological Association (AUA)’s Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s). Designed to showcase the exceptional, groundbreaking studies that are expected to change the day-to-day practice of urology, P2s are reserved for the most impactful studies and will be presented on the Plenary stage. Additionally, CG Oncology will present updates to ongoing clinical trials evaluating cretostimogene across the non-muscle invasive bladder cancer (NMIBC) treatment landscape which are expected to influence urology practice, as well as one interactive poster on translational data. The AUA Annual Meeting, scheduled from April 26-29, 2025, in Las Vegas, Nevada, is the largest gathering of urologists in the world, where leaders in the field share groundbreaking research, new guidelines and the latest advances in urologic medicine.

CG Oncology will have a series of key presentations and updates on cretostimogene grenadenorepvec including:

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ Session: Saturday Morning Plenary Session Presenter: Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona Presentation Date & Time: Saturday, April 26, 2025, 10:40 AM to 10:50 AM PT Location: Venetian Ballroom, The Venetian Convention & Expo Center

IP02-28: Translational Correlates using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Updated Analysis from the BOND-003 and CORE-001 Trials Session: IP02- Bladder Cancer- Non-Invasive I Presenter: Colin P. N. Dinney, MD; Professor and Chairman of the Department of Urology at The University of Texas M D Anderson Cancer Center Presentation Date & Time: Saturday, April 26, 2025, 7:00 AM to 9:00 AM PT Location: Marco Polo 701, The Venetian Convention & Expo Center

Updates to the CORE-008 Trial Protocol: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Session: Clinical Trials in Progress- Bladder Cancer Presenter: Trinity J. Bivalacqua, MD, PhD Professor of Urology and Oncology at the University of Pennsylvania Presentation Date & Time: Monday, April 28, 2025, 9:56 AM to 10:04 AM PT Location: Learning Lab, The Venetian Convention & Expo Center

Trial in Progress: BOND-003 Cohort P- A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Session: Clinical Trials in Progress- Bladder Cancer Presenter: Mark D. Tyson, MD, MPH; Urologic Oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona Presentation Date & Time: Monday, April 28, 2025, 9:40 AM to 9:48 AM PT Location: Learning Lab, The Venetian Convention & Expo Center

Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer Session: Clinical Trials in Progress- Bladder Cancer Presenter: Max Kates, MD, Associate Professor of Urology and Oncology and Director of the Bladder Cancer Program in the Brady Urological Institute at Johns Hopkins Presentation Date & Time: Monday, April 28, 2025, 10:28 AM to 10:36 AM PT Location: Learning Lab, The Venetian Convention & Expo Center Individuals can access the webcast via the link on the company’s Investor Relations website, https://ir.cgoncology.com . An archive will be available following the completion of the call.

” content_last_edited=”on|phone” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Montserrat||||||||” text_text_color=”#000000″ text_font_size=”18px” width_tablet=”” width_phone=”329px” width_last_edited=”on|phone” height_tablet=”” height_phone=”4100px” height_last_edited=”on|phone” custom_margin_tablet=”” custom_margin_phone=”||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”3px|||||” global_colors_info=”{}”]